Based on previous research [35, 36], the efficacy of PARP inhibitors was found to decrease when various chemotherapeutic agents were used, implying that the administration of PARP inhibitors for the early treatment of ovarian cancer could be more beneficial. This evidence concerns the gene PARP1 and ovarian carcinoma.